Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
* The screening period = up to 4 weeks prior to the first administration of combined therapy
* The treatment period = 3 months of combined therapy. A safety follow-up of 42 to 49 days after the last dose of treatment is planned for all patients.
* The follow-up period: Patients who are not progressing at the end of study treatment will be followed until progression or initiation of another anti-lymphoma therapy. All patients will be followed for two years to evaluate survival.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histological diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL)
Relapsed or refractory after at least one standard treatment including rituximab
CD19 and CD20 positive disease
You may not be if
No bi-dimensionally measurable lesion by CT scan (defined as presence of at least one tumor mass measuring \>1.5 x 1.5 cm)
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Clareo Health | Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
